ETNB•benzinga•
89bio Presents New Analyses Evaluating Pegozafermin And Potential Benefit Of Non-Invasive Tests From The ENLIVEN Phase 2b Trial In MASH Patients At AASLD The Liver Meeting 2024
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga